Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe
December 7, 2021
- First round of pricing negotiations completed in the United Kingdom
- TwinPharma and ExCEEd Orphan to commercialize Sibnayal™ in Benelux and Central and Eastern European Countries respectively, covering 25% of all patients affected by dRTA
- Advicenne will receive a combination of transfer price and royalties for an amount markedly higher than 50% of future sales of Sibnayal™